When the HLA alleles significantly associated with FMF, clinical forms of FMF or subgroups of the patients with characteristic MEFV genotypes identified above were analyzed (Table 5), B*35:01 carriers were more likely resistant to colchicine-treatment; 42.9% of 14 treatment-resistant patients and 13.5% of 156 colchicine-responders possessed B*35:01 allele (OR = 4.82, 95% confidence interval of OR: 1.47–15.8, p = 0.0041), satisfying Bonferroni’s collection for multiple statistical tests (n = 11, p<0.0045). This evidence concerns the gene MEFV and familial Mediterranean fever.